HOME >> MEDICINE >> NEWS
Aspirin withdrawal may pose risk to coronary patients

(Orlando, Florida, October 29, 2003) -- Patients with coronary artery disease who stop taking aspirin may be at risk for developing withdrawal-related coronary events, says a new study presented at CHEST 2003, the 69th annual international scientific assembly of the American College of Chest Physicians (ACCP). The study found that previously stable coronary patients experienced coronary events, including unstable angina and myocardial infarction (heart attack), within one week of aspirin withdrawal.

"The benefits of aspirin therapy in coronary patients are well known. However, the effects that aspirin withdrawal has on this group of patients are just now being studied," said lead author Emile Ferrari, MD, Professor of Cardiology, University Hospital Pasteur, Nice, France. "Our study shows that aspirin therapy can not be safely stopped in any case, but especially in patients with a history of coronary disease."

Researchers from University Hospital Pasteur reviewed the cases of 1,236 patients hospitalized for coronary syndromes to determine which patients were hospitalized due to treatment withdrawal. Of those hospitalized, 51patients experienced acute coronary events, including unstable angina, stent thrombosis, and heart attacks, less than one week after aspirin withdrawal. Prior to hospitalization, patients had been taking aspirin for at least three months. Although patients had a history of heart attacks and stable angina, none had an unstable coronary event prior to aspirin withdrawal. Reasons for aspirin withdrawal included minor surgery, dental treatment, and non-compliance. Aspirin therapy is standard in patients with coronary artery disease because of its ability to thin the blood and reduce the risk of developing acute blockage in the coronary arteries.

"Coronary patients preparing for dental work or surgery are often advised to stop taking aspirin in order to avoid increased bleeding," said Dr. Ferrari. "Our study serves as
'"/>

Contact: Arielle Green
agreen@chestnet.org
847-498-8387
American College of Chest Physicians
29-Oct-2003


Page: 1 2

Related medicine news :

1. Aspirins potential ability to prevent colon polyps may not apply equally to all
2. Aspirin underused to reduce heart disease risk in diabetic women and young adults
3. Long Island Breast Cancer Study data: Aspirin helps protect some women against breast cancer
4. Aspirin use associated with reduced risk of breast cancer
5. Aspirin use may be associated with increased risk of pancreatic cancer
6. Aspirin is most cost effective way to prevent heart disease
7. Aspirin does not reduce effectiveness of ACE inhibitors
8. Aspirin may help prevent pancreatic cancer
9. Aspirins target, the COX-2 enzyme, linked to cancer of the uterus
10. Aspirin within two days of ischemic stroke reduces deaths
11. Aspirin steps up as anti-inflammatory for arteries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aspirin withdrawal may pose risk coronary patients

(Date:6/17/2013)... NY (PRWEB) June 17, 2013 The Woodstock ... Blake to attend the Festival this summer, which will be ... through Sunday, August 25th. , Blake professes the benefits ... a day to fuel his world class sprinting abilities. ... volume of fruit is drawing attention. "Yohan Blake believes in ...
(Date:6/17/2013)... City Beach, FL (PRWEB) June 17, 2013 ... higher purpose--fighting hunger. Oceana Naturals LLC, the US distributor ... region of The Bay Area Food Bank ... families, and struggling seniors by seeing that they receive ... Natural Sunscreen and All Natural Moisturizer. Contributions will ...
(Date:6/17/2013)... (June 17, 2013) A team from the New ... Naomi Berrie Diabetes Center of Columbia University has generated ... the features of maturity-onset diabetes of the young (MODY). ... patients to produce induced pluripotent stem (iPS) cells, from ... mouse, the stem cell-derived beta cells secreted insulin in ...
(Date:6/17/2013)... Keller, TX (PRWEB) June 17, 2013 Tarrant ... special. , The term ‘mommy makeover’ has recently undergone ... from surgeon to surgeon. At Tarrant Plastic Surgery, they regard ... procedures designed to remove and reverse many of the effects ... the breast may typically include: drooping of the breast with ...
(Date:6/17/2013)... new drug called pyrvinium pamoate inhibits aggressive forms of ... to a study conducted in an animal model. The ... 95th Annual Meeting in San Francisco. , "Our novel ... action," said study lead author Jeremy Jones, PhD, assistant ... Research Institute, in Duarte, CA. "Thus, it has the ...
Breaking Medicine News(10 mins):Health News:Yohan Blake Invited to The Woodstock Fruit Festival as Guest of Honor 2Health News:All Natural Sunscreen Fights Hunger 2Health News:NYSCF and Columbia researchers demonstrate use of stem cells to analyze causes, treatment of diabetes 2Health News:NYSCF and Columbia researchers demonstrate use of stem cells to analyze causes, treatment of diabetes 3Health News:Tarrant Plastic Surgery Announces Summer Makeover Special 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2
(Date:6/17/2013)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... ENDO 2013, the Endocrine Society,s 95 th ... both melatonin and cortisol rhythms. This effect further ... clock and address the circadian desynchrony which is ... and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study ...
(Date:6/17/2013)... 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... has filed a preliminary prospectus supplement to its effective shelf ... similar filing with securities regulatory authorities in each of the ... a public offering of its common shares to raise gross ... Company will also grant to the underwriters of the Offering ...
(Date:6/17/2013)... June 17, 2013 The following is a Statement ... at Drugfree.org :   Last Friday, ... was halting the sale of prescription drug paraphernalia products. The ... that from time to time there may be individual items ... As a result of this misinterpretation we are electing to ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2
Cached News: